Acrivon Therapeutics

Acrivon Therapeutics

  • Founded: 2018
  • Location: Cambridge, MA
  • Employee range: 1-50
  • Funding: 100-500M

job board

Short description:

Contact us to add description:

Drug notes:

Contact us to add description:

Long description:

Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.


Acrivon Therapeutics
Watertown, Massachusetts, Stati Uniti d'America|16 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy